Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today announced presentation of preclinical ...

VIKTORIA-1 shows gedatolisib maintained strong PFS benefit over alpelisib in PIK3CA-mutant HR+/HER2− breast cancer, including ...

In BV2 microglial cells, esketamine suppressed lipopolysaccharide-induced M1 polarization by selectively acting on the NMDAR2A receptor subtype and activating mTOR and BDNF-TrkB signaling.

Faeth Therapeutics announced presentation of preclinical data at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain, in a poster entitled ?Characterising the efficacy of ...

Fintel reports that on October 16, 2026, William Blair initiated coverage of Revolution Medicines (BMV:RVMD) with an Outperform recommendation. Revolution Medicines, Inc., based in the United States, ...

A query audit of 26 named KEGG signaling pathways in extracellular-vesicle research found that only three PubMed retrievals ...

Kazia Therapeutics (KZIA) stock gains new Buy from Gueggenheim, based on company's lead asset paxalisib, following a similar view from Leerink this week. Read more here.

Limited (“ HUTCHMED ” or the “Company”) (Nasdaq/AIM:HCM; HKEX:13) today announces that further to its announcement on September 3, 2026 and following the completion of customary closing conditions ...

Poster will characterize the efficacy of PIKTOR as a monotherapy and in combination with fulvestrant, oral SERDs, and CDK inhibitors in preclinical models of breast cancer; Poster ...

Researchers follow the children of centenarians to see what longevity and disease-resistance traits they may inherit. The ...

MONARCH shows median OS of 32.1 vs 24.6 months with abemaciclib after prior CDK4/6 therapy, but the survival difference was ...